Cardinal Health, Inc. (CAH) Income Statement

The reported TTM revenue growth is exceptionally high, likely driven by acquisitions, masking underlying organic growth trends. Quarterly year-over-year growth has decelerated from 22.4% in 2026Q1 to 6.1% in 2026Q4, suggesting the inorganic boost may be fading and core distribution growth is stabilizing at a moderate pace. This volatility warrants scrutiny of the sustainability of top-line expansion beyond integration periods.

The gradual improvement in gross margin suggests some benefits from product mix shifts, possibly toward higher-margin generic drugs or medical products. However, the margin remains under 5%, which is typical for the oligopolistic drug distribution sector but leaves little buffer for cost inflation or pricing pressures. Investors should monitor the balance between branded and generic mix, as well as the impact of any manufacturer rebate changes.

The expansion in operating margin from 0.7% to 1.1% over the same period demonstrates that SG&A expenses have not grown proportionally with revenue, likely due to fixed cost absorption and efficiency initiatives. This operating leverage has been a key driver of earnings growth, but its durability depends on maintaining volume growth without proportional increases in distribution and administrative costs.

Prior to 2025Q3, operating margins had been stuck in the 0.7%-1.1% range. The jump to 1.3% marked a turning point, coinciding with a shift from revenue declines to modest growth. This inflection appears to be structural, as operating margins have remained at or above 1.0% in subsequent quarters, suggesting that management's cost discipline and operational improvements have gained traction.